Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABOSTO:MCAP +3.86%78 Debt-to-Equity is 0.29 as of Jun. 2026, which is 28% below its 10-year median of 0.40. GuruFocus rates OSTO:MCAP with a GF Score™ of 78/100 and a GF Value™ of kr574.74 (Fairly Valued). Among 703 Medical Devices & Instruments companies, MedCap AB ranks worse than 56.19% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MedCap AB's Debt-to-Equity or its related term are showing as below:
OSTO:MCAP'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 0.4 Max: 1.12
Current: 0.29
During the past 13 years, the highest Debt-to-Equity Ratio of MedCap AB was 1.12. The lowest was 0.25. And the median was 0.40.
OSTO:MCAP's Debt-to-Equity is ranked worse than 56.19% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs OSTO:MCAP: 0.29
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MedCap AB Debt-to-Equity Related Terms
MedCap AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for MedCap AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MCAP vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, MedCap AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MedCap AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedCap AB (OSTO:MCAP) has a Debt-to-Equity of 0.29 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MedCap AB and its competitors. This is 28% below median its historical median of 0.40. Over the past decade, MedCap AB's Debt-to-Equity has ranged from 0.25 to 1.12. According to the industry distribution chart, MedCap AB ranks #395 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 56.2%.
Is MedCap AB's Debt-to-Equity too high?
MedCap AB's current Debt-to-Equity of 0.29 is 28% below median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 1.12. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. MedCap AB's value of 0.29 is 26.1% above this industry median. Based on the distribution chart, MedCap AB ranks #395 out of 703 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MedCap AB has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #395 out of 703 companies for Debt-to-Equity. This places MedCap AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. MedCap AB's value of 0.29 is 26.1% above this benchmark. Historically, MedCap AB's own Debt-to-Equity has ranged from 0.25 to 1.12 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 0.23, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current Debt-to-Equity of 0.29 is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current Debt-to-Equity is 0.29, which is 28% below median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr574.74, compared to a current price of kr551.50 — trading 4% below its estimated fair value. The current Debt-to-Equity is 0.29, which is 28% below median its 10-year median of 0.40 and 26.1% above the Medical Devices & Instruments industry median of 0.23. MedCap AB's overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current Debt-to-Equity is 0.29 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (OSTO:MCAP) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr551.50 is trading 4% below its estimated GF Value™ of kr574.74.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for OSTO:MCAP:
Debt-to-Equity: 0.29 (28% below median its 10-year median of 0.40)
GF Value™: kr574.74 vs. price of kr551.50 (4% below fair value)
Industry Position: 26.1% above the Medical Devices & Instruments median (#395 of 703)
No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
78GF Score
Get the complete analysis for OSTO:MCAP
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MCAP has been successfully added to your 
